The global Malaria Vaccines Market is entering a transformative phase, driven by growing public health concerns, government support for immunization programs, and increasing efforts to develop next-generation vaccines targeting the Plasmodium falciparum parasite. With malaria remaining a significant burden in low- and middle-income countries, particularly across Africa and parts of Asia and Latin America, the demand for effective vaccination solutions has never been greater.
Global Malaria Vaccines Market size and share is currently valued at USD 491.90 million in 2024 and is anticipated to generate an estimated revenue of USD 1,619.87 million by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 12.7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
Market Overview
Malaria, a life-threatening disease caused by Plasmodium parasites and transmitted via Anopheles mosquitoes, remains one of the top five causes of death in many parts of sub-Saharan Africa. Among the various species, Plasmodium falciparum accounts for the majority of severe cases and fatalities. In response to this public health emergency, the World Health Organization (WHO) endorsed RTS,S/AS01 (Mosquirix) in 2021—the world’s first malaria vaccine approved for widespread pediatric use.
The global burden of the disease, coupled with renewed policy emphasis on vector control and preventive healthcare, is spurring governments and stakeholders to accelerate malaria vaccine adoption. Market activity is intensifying, with several candidates under development, especially those offering higher efficacy, improved stability, and compatibility with existing child immunization schedules.
Market Segmentation
By Vaccine Type
RTS,S/AS01 (Mosquirix)
Developed by GSK and endorsed by WHO, this is currently the only vaccine approved for use in children.
R21/Matrix-M
A promising next-gen vaccine developed by Oxford University and manufactured by Serum Institute of India. It has demonstrated higher efficacy in clinical trials and is pending widespread rollout.
PfSPZ Vaccine
Developed by Sanaria, this whole-sporozoite vaccine remains in clinical testing and is designed to offer long-term protection.
By Application
Pediatric Malaria Vaccine
The primary focus area for vaccine developers due to high vulnerability and mortality rates in children under five.
Adult Malaria Vaccine
Though not widely available yet, trials are underway to develop vaccines suitable for adult travelers and military personnel.
By Distribution Channel
Public Health Agencies
Major buyers and distributors through national immunization programs.
Non-Governmental Organizations (NGOs)
Entities such as Gavi, UNICEF, and Médecins Sans Frontières distribute vaccines in collaboration with governments.
Private Healthcare Providers
Emerging but limited market, mostly in urban centers of developing countries and for travelers in developed nations.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/malaria-vaccines-market
Country-wise Market Trends
Ghana
Ghana was one of the first countries to implement the RTS,S vaccine through WHO’s pilot program. Following successful outcomes, the government integrated malaria vaccination into its national immunization strategy. The rollout is now expanding to include R21/Matrix-M as it becomes available.
Kenya
Kenya’s robust healthcare infrastructure and early adoption of malaria vaccination have positioned it as a regional leader in vector control and prevention. National data shows a significant reduction in pediatric malaria admissions, and the government is now pushing for broader rural coverage.
India
India, which accounts for a large share of malaria cases in South Asia, is ramping up domestic production and trial of malaria vaccines. With support from the Serum Institute and Bharat Biotech, the country is poised to become a major supplier to the Asia-Pacific region and parts of Africa.
Nigeria
As the country with the highest malaria burden globally, Nigeria has become a focal point for vaccination efforts. In 2024, the government announced a USD 250 million partnership with Gavi to scale the delivery of pediatric malaria vaccines through public hospitals and mobile clinics.
Uganda
Uganda is witnessing increasing funding for vaccine research and trials, especially in northern regions where malaria prevalence is highest. The country is piloting community-based delivery systems to reach remote populations.
Brazil
Although malaria is largely confined to the Amazon Basin, Brazil is investing in vaccine development and clinical trials to combat seasonal outbreaks. Partnerships with international research organizations are accelerating the country's involvement in the market.
Democratic Republic of Congo (DRC)
With one of the highest incidence rates of malaria, the DRC is receiving substantial international aid to implement routine vaccinations. The deployment of cold chain solutions and rural healthcare workers is helping improve access in underserved areas.
Tanzania
Tanzania is emerging as a case study for successful vaccine implementation, with data showing a 40% drop in severe pediatric malaria cases since RTS,S introduction. The country plans to integrate R21 into its immunization program by 2026.
Key Companies in the Malaria Vaccines Market
1. GSK (GlaxoSmithKline plc)
GSK leads the market with its RTS,S/AS01 (Mosquirix) vaccine. In partnership with PATH and WHO, GSK is scaling production to meet global demand. The company is also working on second-generation candidates aimed at improving efficacy and shelf life.
2. Serum Institute of India
The Serum Institute is at the forefront of manufacturing the R21/Matrix-M vaccine. With a target of producing over 100 million doses annually, it is well-positioned to become a global supplier, especially to African nations.
3. Sanaria Inc.
This U.S.-based biotech firm is pioneering the development of the PfSPZ vaccine, using irradiated sporozoites to generate robust immunity. Though still undergoing trials, Sanaria’s approach is considered highly innovative in malaria vaccine research.
4. Bharat Biotech
In addition to its COVID-19 vaccine success, Bharat Biotech is developing malaria vaccines targeting both adults and children. The company is collaborating with Indian government agencies and global health organizations for clinical testing.
5. BioNTech
Expanding its mRNA platform beyond COVID-19, BioNTech is working on a malaria vaccine candidate using mRNA technology. Trials are being conducted in Rwanda and Ghana, with early results expected by late 2025.
6. Novavax
Known for its recombinant nanoparticle-based vaccines, Novavax is conducting exploratory research into malaria vaccines. Its Matrix-M adjuvant is already being used in R21, in collaboration with Oxford University and Serum Institute.
Conclusion
The Malaria Vaccines Market is evolving into a high-growth sector as developing nations intensify their commitment to eradicating malaria. With significant progress in vaccine development, increased international funding, and integration into national immunization programs, the global health community is better equipped than ever to combat one of the deadliest vector-borne diseases.
While challenges such as limited cold chain infrastructure, vaccine hesitancy, and manufacturing constraints remain, the collaboration between governments, NGOs, and private companies is beginning to yield measurable impact.
As countries from Ghana to India and Nigeria to Brazil commit to scaling malaria vaccine distribution, the next five years are expected to bring a paradigm shift in how the disease is prevented, especially among vulnerable pediatric populations. With technology advancing and production scaling, the vision of a malaria-free generation is steadily becoming attainable.
More Trending Latest Reports By Polaris Market Research:
Narcolepsy Therapeutics Market
Bipolar Disorder Treatment Market
Brain Tumor Diagnosis and Therapeutics Market
Flexible Paper Packaging Market
X-Ray Photoelectron Spectroscopy Market
Disinfection And Sterilization Equipment Market
Infectious Disease Diagnostics Market
Percutaneous Coronary Intervention (Pci) Devices Market
Peptide Based Cancer Therapeutics Market
Zollinger-Ellison Syndrome Treatment Market
Clinical Operations and Development Market: Major Strategic Developments Listed
Analyzing Top 5 Companies Driving Growth in Non-Invasive Prenatal Testing (NIPT) Market
